Russia’s Peptogen launches production of innovative CV drugs

20 August 2014

Sergei Sobyanin, Mayor of Moscow, has officially launched a new Russian plant for the production of innovative drugs for the prevention and treatment of heart attacks.

The new plant is operated by local Peptogen company, one of Russia’s largest developers of peptide drugs and is located at Strogino Technopark.

“Technoparks are being actively promoted in Moscow. They are specially-designed platforms for creating innovative high-tech products. A new facility has been opened in Strogino Technopark today, manufacturing medication for the prevention and treatment of strokes. This is a key direction, capable of decreasing stroke mortality rates, which has become a major problem in modern medicine,” said Mayor Sobyanin.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >